Ivermectin for Covid, The Failure of American Medicine

Ivermectin for Covid, The Failure of American Medicine

The FLCCC Group led by Drs Paul Marik and Dr Pierre Kory have reviewed massive amounts of data from medical studies showing Ivermectin to be highly effective repurposed anti-viral drug. (1)(10)(21)(24)

The international study data is massive and overwhelming showing dramatic reduction in mortality from the Covid-19 virus for hospitalized patients (70-90%).  In addition, the data shows excellent prevention of Covid 19 disease when the drug is used for prophylaxis in high risk groups.

Dr Jackie Stone discusses the use of Ivermectin in Zimbabwe

In this video interview with Dr. Eric Osgood, Jackie Stone MD  discusses the use of ivermectin in Zimbabwe, (17)  Dr. Stone is a front line doctor in the early use of Ivermectin against Covid 19.  Dr Stone advocates that ivermectin should be quickly prescribed for prophylaxis and early treatment of the virus. Dr Stone shares her own harrowing experience as a COVID-19 patient, contracting the virus twice.  Dr Stone describes her own hypoxic pulmonary symptoms with dropping O2 saturation and shortness of breath, thought to be due to platelet activation, clumping and vascular occlusion  by the virus as described by Dr David Scheim. (18)  She felt immediate relief of the shortness of breath symptoms shortly after taking the Ivermectin dose, ascribed to the alleviation of CD-147 mediated vascular occlusion. (18)

COVID 19 Virus Causes Platelet Clumping and Capillary Occlusion in Lungs.  This causes Hypoxia and Decreased O2 Saturation. Promptly Relieved by Ivermectin !!!!  Younger people are spared because of higher rate of capillary blood flow.

Dr David Scheim (2020) writes:

“IVM (Ivermectin) shields  (the) SARS-CoV-2 spike protein and … this spike protein binds to the CD147 transmembrane receptor as well as to ACE2. The abundant distribution of CD147 on red blood cells (RBCs) suggests a hypothesized “catch” and “clump” framework whereby virally-mediated bindings of RBCs to other RBCs, platelets, white blood cells and capillary walls impede blood flow, which in turn may underlie key morbidities of COVID-19.

The proposed catch and clump scenario for COVID-19 has a parallel in malaria, for which CD147 is central to the infectious process. The core morbidity of severe malaria is caused by similar clumps and adhesions to endothelium centering around infected RBCs. These underlie the much greater incidence of severe malaria for blood groups A or B vs. O, caused by adhesive RBC membrane trisaccharides associated with blood groups A and B. COVID-19 is likewise much more prevalent for blood groups A or B vs. O.

More generally, hemagglutination, the formation of such RBC-pathogen clusters, is common for enveloped viruses. Under this hypothesized framework, a significantly higher rate of capillary flow in younger people could explain a corresponding decreased severity of COIVD-19. This proposed hypothesis and the associated potential for major IVM dose-response gains could be tested, for example, by monitoring blood flow in COVID-19 patients before and after IVM intake using nailfold capillaroscopy.” end quote (18)

This Explains the Frustration Expressed by Dr. Carmeron Kyle-Sidell last Year March 2020 in NYC during the Early Days of the Covid Pandemic.

Dr. Carmeron Kyle-Sidell, an ICU specialist and ER doctor in NYC made the observation that hypoxic ICU patients with corona virus (Covid-19) do not have typical ARDS (Adult Respiratory Distress Syndrome), and    placing these patients on ventilators is a mistake and causes more harm.  Dr Sidell says the correct treatment is high flow oxygen by mask or nasal canula without positive pressure mechanical ventilation.  Use of ventilators should be delayed as long as possible.

Now We Know the Mechanism Producing the Hypoxia

In the early days of the Covid-19 pandemic, doctors were unaware that hypoxia was the result of viral induced platelet aggregation and micro-thombosis causing capillary occlusion in the pulmonary vasculature.  Now, a year later, doctors such as Dr David Scheim have described the viral mechanism producing the hypoxia.(18)  Ventilators cause more harm and should be avoided.

Instead, symptoms of hypoxia are relieved by the repurposed antiviral drug, Ivermectin, in conjunction with anti-platelet agents.  This also explains the high mortality rate when using ventilators for the hypoxia of Covid 19, a pulmonary microangiopathy, capillary microvascular occlusion.  The syndrome was worsened by baro-trauma from positive pressure ventilators in NYC hospitals in the early months of the pandemic (March 2020).

Now We Can Understand This

A year ago, I watched this video of Dr Carmeron Kyle-Sidell reporting his hypoxic Covid patients in the ICU look more like “High-Altitude Sickness” than ARDS viral pneumonia.   A year ago, I did not understand this. Now I do.

Dr. Carmeron Kyle-Sidell : You tube presentation can be found here.

Ivermection Distribution Campaigns

Africa Ivermectin (APOC) Vs Non-APOC Countries

Data from 19 countries that participated in the World Health Organization (WHO) sponsored African Programme for Onchocerciasis Control (APOC), from 1995 until 2015, were compared with thirty-five (Non-APOC), references:

Guerrero, Rodrigo, et al. “COVID-19: The ivermectin African enigma.” Colombia Médica 51.4 (2020).  19 Counties  WHO African Programme for Onchocerciasis Control (APOC),

Yagisawa, Morimasa, et al. “Global trends in clinical studies of ivermectin in COVID-19.” The japanese journal of antibiotics 74 (2021): 1.

India: Sept 4, 2021 –  Ivermectin Distribution – 24 Covid-19 Free Districts in Utter Pradesh India

Mexico:  Chiapas vs every other State in Mexico

Epidemiologic Analyses on COVID-19 and Ivermectin Published on May 13, 2021  Written by Juan Chamie https://principia-scientific.com/epidemiologic-analyses-on-covid-19-and-ivermectin/

Peru Ivermectin Distribution IVM Campaign, 14  fold decrease in Covid cases after Ivermectin distribution. 13-fold increase when Ivermectin restricted.

Chamie-Quintero, Juan, Jennifer A. Hibberd, and David Scheim. “Ivermectin for COVID-19 in Peru: 14-fold reduction in nationwide excess deaths, p=. 002 for effect by state, then 13-fold increase after ivermectin use restricted.” (2021).

The Failure of American Medicine

We now have convincing data showing Ivermectin to be effective drug for prevention and treatment of Covid-19. (31)  In addition multiple mechanisms of antiviral action have been uncovered, both against the virus as well as supporting the host.  As Dr Paul Marik points out in his discussions, the complete disregard for Ivermectin as a preventive drug and effective treatment for Covid -19 by the leadership US government agencies, the CDC, NIH and FDA represents a horrendous failure of American Medicine.

Above Image I-MAsk Proctocol: Kory, Pierre, et al. “Clinical and scientific rationale for the “MATH+” hospital treatment protocol for COVID-19.” Journal of intensive care medicine 36.2 (2021): 135-156.

Header image: Bellevue Hospital Surgeons Get Ready courtesy of NYC Heath Hospitals Bellevue AAMC.

Update May 25, 2021: Michael Capuzzo, a New York Times best-selling author, published article on Ivermectin for COVID,  “The Drug That Cracked Covid”.  The-Drug-that-Cracked-Covid-by-Michael-Capuzzo Mountain Home Magazine May 2021

Update 8/13/21: India’s Ivermectin Blackout Friday, Aug 13, 2021 by Justus R Hope, MD. via TheDesertReview.com,

Update 8/21/21: Health officials warn people not to treat Ĉ0\/id with a drug meant for livestock.” The New York Times is Guilty of Fake l\/ërmëctin News Reporting and Medical Malfeasance. How many people will die of Ĉ0\/id without the benefit of early treatment with l\/ërmëctin because of this blatantly false New York Times article ? l\/ërmëctin is FDA approved, readily available at all US pharmacies and freely prescribed by pediatricians for children with scabies (mites). And yes, l\/ërmëctin is used in veterinary medicine for billions of farms animals and pets (dogs) . l\/ërmëctin is considered “Astonishingly Safe”, a “Wonder Drug”. The Nobel Prize in medicine was awarded to two doctors for its discovery. This New York Times article is a disgrace to journalism.

Having Trouble Finding a Doctor Who will Prescribe Ivermectin for Covid?
Click here: Telemedicine Services for Covid Treatment List of Providers

Having Trouble Finding a Pharmacy that will Fill your Ivermectin Prescription?

All U.S. citizens in need of an ivermectin prescription are able to identify the nearest pharmacy that has inventory by emailing or calling Edenbridge Pharmaceuticals, the manufacturer of Ivermectin.
Email: sales@edenbridgepharma.com
Telephone: 201-292-1292

How to Obtain Ivermectin PDF

Compounding Pharmacies that Supply Ivermectin in the US:

Pharmacies Supplying Ivermectin

CustomRx
3510 N Ridge Rd. #900
Wichita, KS 67205
P: 316 721 2626
Fx: 316 721 4823

Canadian Pharmacy King
(877) 745-9217
customerservice@canandianpharmacyking.com
Prescription Required

United Pharmacies
(888) 256-3135
No prescription required, search for Stromectol

Honeybee Pharmacy
(833) 466-3979
support@honeybeehealth.com
Prescription Required

Portico Pharmacy
(208) 288-4341
3355 E. L Louise Drive, Meridian, Idaho, 83642
Prescription Required

Value Pharmacy
(702) 331-0449
valuerx@gmail.com
3380 W. Ann Rd, Ste 110, Las Vegas, NV 89031
Prescription Required

The Compounding Lab Pharmacy
(423) 328-9333
714 W. Market St., Ste 101
Johnson City, TN 37604
Prescription Required

MidCities Pharmacy
(817) 605-3500
Hurst, TX
Prescription Required

The Medicine Shop Pharmacy
10720 State Rd, 54, Ste 103, Trinity, FL 34655
(727) 375-2502

Nei’s Compounding Pharmacy
9801 Kincey Ave, Huntersville, NC 28078
(704) 947-3220

Austin Compounding Pharmacy
3010 Bee Cave Rd, Ste, 100, Austin, TX 78746
(512) 327-7455

=======================================================

The Association of American Physicians and Surgeons (AAPSonline.org)
Early Home  Covid Patient Treatment Guide

=========================================================

Articles with Related Interest:

Early Treatment PPT Slide Set Early Treatment Slide Set AAA1

Robert Malone on the Covid War Games

Israel Should Stop Pfizer and start Ivermectin

Ivermectin Antiparasitic Anticancer Antiviral Wonder Drug

Covid Conversation Round Table San Juan Global Covid Summit

More Cov-idiocy from the Clown Department

Casualties of the C0\/lD War, When Wlll this End ?

Rochelle Wolensky Warns of ADE Antibody Dependent Enhancement

Dr Peter McCullough on Early Treatment vs Vaccination

Covid Vaccines Are Safe and Effective ?

Are Covid Vaccines the Next Vioxx ?

Ivermectin Antiparasitic Anticancer Miracle Drug

Vaccinoffee, a Vaccine with Every Coffee

Herbal Antivirals for Covid 19 and other Viruses

Vitamin D for Corona Virus Instead of a Vaccine ?

Protecting Yourself from Corona virus Part Two

Protecting Yourself from Corona virus Part One

Effective Early Treatment for Corona Virus

Hydroxychloroquine Effective for Corona Virus

Vitamin D for Corona Virus Instead of Vaccine

Jeffrey Dach MD
7450 Griffin Road
Suite 180/190
Davie, Fl 33314
954-792-4663

 

References

1) Ivermectin reduces the risk of death from COVID-19 -a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance. (Latest version v1.2 – 6 Jan 2021) January 2021 Project: Ivermectin to prevent and treat COVID-19 Authors: Theresa A Lawrie

2) Dixit, Alok, Ramakant Yadav, and Amit Vikram Singh. “Ivermectin: potential role as repurposed drug for COVID-19.” The Malaysian journal of medical sciences: MJMS 27.4 (2020): 154.

IVM which is a widely used as antiparasitic drug has shown to have antiviral activity in in vitro studies against HIV, dengue, influenza, VEEV and Zika virus. The broad-spectrum antiviral activity of IVM against both RNA and DNA viruses offers an added advantage to its potential use over other antiviral drugs. Studies are available for its use against RNA virus and have also been tested for its effectiveness against SARS-CoV-2 in vitro. Based on evidences it seems prudent to use IVM empirically and conduct well designed controlled randomised trials to prove its efficacy in vivo.

3) Chamie-Quintero, Juan, Jennifer A. Hibberd, and David Scheim. “Ivermectin for COVID-19 in Peru: 14-fold reduction in nationwide excess deaths, p=. 002 for effect by state, then 13-fold increase after ivermectin use restricted.” (2021).

Introduction. On May 8, 2020, Peru’s Ministry of Health approved ivermectin (IVM), a drug of Nobel Prize-honored distinction, for inpatient and outpatient treatment of COVID-19. As IVM treatments proceeded in that nation of 33 million residents, excess deaths decreased 14-fold over four months through December 1, 2020, consistent with clinical benefits of IVM for COVID-19 as have emerged in several RCTs. But after IVM use was sharply restricted under a new president, excess deaths then increased 13-fold.
Methods. To evaluate possible IVM treatment effects suggested by these aggregate trends, excess deaths were analyzed by state for ages ≥ 60 in Peru’s 25 states. To identify potential confounding factors, Google mobility data, population densities, SARS-CoV-2 genetic variations and seropositivity rates were also examined.
Results. The 25 states of Peru were grouped by extent of IVM distributions: maximal (mass IVM distributions through operation MOT, a broadside effort led by the army); medium (locally managed IVM distributions); and minimal (restrictive policies in one state, Lima). The mean reduction in excess deaths 30 days after peak deaths was 74% for the maximal IVM distribution group, 53% for the medium group and 25% for Lima. Reduction of excess deaths is correlated with extent of IVM distribution by state with p<0.002 using the Kendall τb test.
Conclusion. Mass treatments with IVM, a drug safely used in 3.7 billion doses worldwide since 1987, most likely caused the 14-fold reductions in excess deaths in Peru, prior to their 13-fold increase after IVM policy was reversed. This strongly suggests that IVM treatments can likewise effectively complement immunizations to help eradicate COVID-19. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, possibly yielding full efficacy against emerging viral mutant strains.

4) Lehrer, Steven, and Peter H. Rheinstein. “Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2.” in vivo 34.5 (2020): 3023-3026.

We used the program AutoDock Vina Extended to perform the docking study. Results: Ivermectin docked in the region of leucine 91 of the spike and histidine 378 of the ACE2 receptor. The binding energy of ivermectin to the spike-ACE2 complex was -18 kcal/mol and binding constant was 5.8 e-08. Conclusion: The ivermectin docking we identified may interfere with the attachment of the spike to the human cell membrane.

5) Vora, Agam, et al. “White paper on Ivermectin as a potential therapy for COVID-19.” indian journal of tuberculosis 67.3 (2020): 448-451.

“Ivermectin in the dose of 12 mg BD alone or in combination with other therapy for 5 to 7 days may be considered as safe therapeutic option for mild moderate or severe cases of Covid-19 infection. It is cost effective especially when the other drugs are very costly & not easily available”.

6) López-Medina E, et al. “Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. JAMA. 2021 Mar 4:e213071.

Importance: Ivermectin is widely prescribed as a potential treatment for COVID-19 despite uncertainty about its clinical benefit.

Objective: To determine whether ivermectin is an efficacious treatment for mild COVID-19.

Design, setting, and participants: Double-blind, randomized trial conducted at a single site in Cali, Colombia. Potential study participants were identified by simple random sampling from the state’s health department electronic database of patients with symptomatic, laboratory-confirmed COVID-19 during the study period. A total of 476 adult patients with mild disease and symptoms for 7 days or fewer (at home or hospitalized) were enrolled between July 15 and November 30, 2020, and followed up through December 21, 2020.

Intervention: Patients were randomized to receive ivermectin, 300 μg/kg of body weight per day for 5 days (n = 200) or placebo (n = 200).

Main outcomes and measures: Primary outcome was time to resolution of symptoms within a 21-day follow-up period. Solicited adverse events and serious adverse events were also collected.

Results: Among 400 patients who were randomized in the primary analysis population (median age, 37 years [interquartile range {IQR}, 29-48]; 231 women [58%]), 398 (99.5%) completed the trial. The median time to resolution of symptoms was 10 days (IQR, 9-13) in the ivermectin group compared with 12 days (IQR, 9-13) in the placebo group (hazard ratio for resolution of symptoms, 1.07 [95% CI, 0.87 to 1.32]; P = .53 by log-rank test). By day 21, 82% in the ivermectin group and 79% in the placebo group had resolved symptoms. The most common solicited adverse event was headache, reported by 104 patients (52%) given ivermectin and 111 (56%) who received placebo. The most common serious adverse event was multiorgan failure, occurring in 4 patients (2 in each group).

Conclusion and relevance: Among adults with mild COVID-19, a 5-day course of ivermectin, compared with placebo, did not significantly improve the time to resolution of symptoms. The findings do not support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes.

the relatively young and healthy study population rarely developed complications, rendering the study the ability of ivermectin to prevent the progression of mild COVID-19 to more severe stages would need to be assessed in larger trials.

the study population was relatively young, with few comorbidities and with liver enzyme levels less than 1.5 times the normal level, so the findings may be generalizable only to such populations.

7) Scheim, David, Jennifer A. Hibberd, and Juan Chamie-Quintero. “Protocol violations in López-Medina et al.: switched ivermectin (IVM) and placebo doses, failure of blinding, indicators of over-the-counter IVM use by controls, and blatant conflicts of interest.” (2021).

Conclusion
Given AEs distinctive for IVM use in study controls and failures of blinding and boundaries between IVM and placebo arms, results for study controls are unreliable. Some useful information can nevertheless be salvaged from outcomes for this study’s IVM treatment arm, in which no deaths and generally mild symptoms occurred, with AEs typical for high-dose IVM (replicated in the control group) that were generally mild and transient.

8) Scheim, David. “Ivermectin sales in Valle del Cauca, Colombia, patterns of AEs, and other background re López-Medina et al. 2021.” (2021).

9) Podder, Chinmay Saha, et al. “Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study.” IMC Journal of Medical Science 14.2 (2020): 1-8.
Background and objectives: Various existing non-antiviral drugs are being used to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection based mostly on existing data from previous coronavirus outbreaks. Ivermectin is one of such agents being widely used to treat early-stage of COVID-19. This study evaluated the outcome of ivermectin treated mild to moderate COVID-19 cases compared to usual care.

Methods: This open-label randomised controlled study was conducted at a sub-district (Upazila) health complex from 1st May 2020 to the end of July 2020. Consecutive RT-PCR positive eligible COVID-19 patients were randomised into control and intervention arms. In the intervention arm, ivermectin 200 micrograms/kg single dose was administered orally in addition to usual care and was followed up till recovery. Repeat RT-PCR was done on day ten since the first positive result. The end point with regard to treatment outcome was time required for the resolution of symptoms from the onset of the symptoms and following enrollement in the study.

Results: A total of 62 mild to moderate COVID-19 patients were enrolled in the study. There were 30 patients in the control arm and 32 patients in the intervention arm. Total recovery time from the onset of symptoms to complete resolution of symptoms of the patients in the intervention arm was 10.09 ± 3.236 days, compared to 11.50 ± 5.32 days in the control arm (95% CI -0.860,3.627, p>. 05) and was not significantly different. The mean recovery time after enrolment in the intervention arm was 5.31 ± 2.48 days, which also did not differ significantly from the control arm of 6.33 ± 4.23 days (95% CI – 0.766, 2.808, p> 0.05). Results of negative repeat RT- PCR were not significantly different between control and intervention arms (control 90% vs intervention 95%, p>.05).

Conclusion: Ivermectin had no beneficial effect on the disease course over usual care in mild to moderate COVID-19 cases.

—————————————————-

10) Kory, Pierre, et al. “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.” (2020).

In March 2020, the Front Line COVID-19 Critical Care Alliance (FLCCC) was created and led by Professor Paul E. Marik to continuously review the rapidly emerging basic science, translational, and clinical data to develop a treatment protocol for COVID-19. The FLCCC then recently discovered that ivermectin, an anti-parasitic medicine, has highly potent anti-viral and anti-inflammatory properties against COVID-19. They then identified repeated, consistent, large magnitude improvements in clinical outcomes in multiple, large, randomized and observational controlled trials in both prophylaxis and treatment of COVID-19. Further, data showing impacts on population wide health outcomes have resulted from multiple, large “natural experiments” that occurred when various city mayors and regional health ministries within South American countries initiated “ivermectin
distribution” campaigns to their citizen populations in the hope s the drug would prove effective. The tight, reproducible, temporally associated decreases in case counts and case fatality rates in each of those regions compared to nearby regions without such campaigns, suggest that ivermectin may prove to be a global solution to the pandemic. This was further evidenced by the recent incorporation of ivermectin as a prophylaxis and treatment agent for COVID-19 in the national treatment guidelines of Belize, Macedonia, and the state of Uttar Pradesh in Northern India, populated by 210 million people. To our knowledge, the current review is the earliest to compile sufficient clinical data to demonstrate the strong signal of therapeutic efficacy as it is based on numerous clinical trials in multiple disease phases. One limitation is that half the controlled trials have been published in peer reviewed publications, with the remainder taken from manuscripts uploaded to medicine pre-print servers. Although it is now standard practice for trials data from pre-print servers to immediately
influence therapeutic practices during the pandemic, given the controversial therapeutics adopted as a result of this practice, the FLCCC argues that it is imperative that our major national and international health care agencies devote the necessary resources to more quickly validate these studies and confirm the major, positive epidemiological impacts that have been recorded when ivermectin is widely distributed among populations with a high incidence of COVID-19 infections.

11) Why aren’t we using Ivermectin? With Dr Tess Lawrie
Why Are We Not Using Ivermectin For Covid? Dr Tess Lawrie MBBCh, DFSRH, PhD
The Evidence-based Medicine Consultancy Ltd and EbMCsquared, Bath, UK
Truth Over Fear Summit, 7 May 2021

12) Dr. Ryan Cole, CEO and Medical Director of Cole Diagnostics regarding Covid, vaccine, & treatments.  Mar 26, 2021

13) Ivermectin Evidence with Dr Tess Lawrie
Published on 12 Mar 2021 / In News and Politics

14) Ivermectin meta-analysis – the findings – Dr Tess Lawrie
Premiered Jan 26, 2021

15) Ivermectin reduces the risk of death from COVID-19 -a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance. (Latest version v1.2 – 6 Jan 2021)

January 2021  Project: Ivermectin to prevent and treat COVID-19 Authors:Theresa A Lawrie

16) Chamie-Quintero, Juan J., Jennifer Hibberd, and David Scheim. “Sharp reductions in COVID-19 case fatalities and excess deaths in Peru in close time conjunction, state-by-state, with ivermectin treatments.” State-By-State, with Ivermectin Treatments (January 12, 2021) (2021).

These sharp major reductions in COVID-19 mortality following IVM treatment thus occurred in each of Peru’s states, with such especially sharp reductions in close time conjunction with IVM treatments in each of the nine states of operation MOT. Its safety well established even at high doses, IVM is a compelling option for immediate, large scale national deployments as an interim measure and complement to pandemic control through vaccinations.

17) FLCCC WEEKLY UPDATE – Dr Eric Osgood talks to Dr. Jackie Stone of Zimbabwe
Apr 8, 2021 FLCCC Weekly Update April 7, 2021.

In this episode, Dr. Eric Osgood discusses the use of ivermectin in Zimbabwe with Dr. Jackie Stone. Dr. Stone has been leading the way in her country to save as many people as possible by ensuring that ivermectin can be quickly and easily obtained for prophylaxis and early treatment. Plus, she shares her own harrowing journey as a COVID-19 patient herself—having contracted the disease twice.

18) Scheim, David. “Ivermectin for COVID-19 treatment: clinical response at quasi-threshold doses via hypothesized alleviation of CD147-mediated vascular occlusion.” Available at SSRN 3636557 (2020).

in several clinical studies, IVM at doses of up to 2,000 µg/kg, ten times that used in the Florida study, were well tolerated. The potential for major dose-response gains is evaluated based upon studies indicating that IVM shields SARS-CoV-2 spike protein and that this spike protein binds to the CD147 transmembrane receptor as well as to ACE2. The abundant distribution of CD147 on red blood cells (RBCs) suggests a hypothesized “catch” and “clump” framework whereby virally-mediated bindings of RBCs to other RBCs, platelets, white blood cells and capillary walls impede blood flow, which in turn may underlie key morbidities of COVID-19. The proposed catch and clump scenario for COVID-19 has a parallel in malaria, for which CD147 is central to the infectious process. The core morbidity of severe malaria is caused by similar clumps and adhesions to endothelium centering around infected RBCs. These underlie the much greater incidence of severe malaria for blood groups A or B vs. O, caused by adhesive RBC membrane trisaccharides associated with blood groups A and B. COVID-19 is likewise much more prevalent for blood groups A or B vs. O. More generally, hemagglutination, the formation of such RBC-pathogen clusters, is common for enveloped viruses. Under this hypothesized framework, a significantly higher rate of capillary flow in younger people could explain a corresponding decreased severity of COIVD-19. This proposed hypothesis and the associated potential for major IVM dose-response gains could be tested, for example, by monitoring blood flow in COVID-19 patients before and after IVM intake using nailfold capillaroscopy.

19) Hellwig, Martin D., and Anabela Maia. “A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin.” International journal of antimicrobial agents 57.1 (2021): 106248.

Here, we show that countries with routine mass drug administration of prophylactic chemotherapy including ivermectin have a significantly lower incidence of COVID-19.

20) COVID-19 Causes ‘Hyperactivity’ in Blood-Clotting Cells Jun 29, 2020 12:00 AM  Doug Dollemore Senior Science Writer, University of Utah Health

21) Zaid, Younes, et al. “Platelets can contain SARS-CoV-2 RNA and are hyperactivated in COVID-19.” medRxiv (2020).
We document the presence of SARS-CoV-2 RNA in platelets of COVID-19 patients. Exhaustive assessment of cytokines in plasma and in platelets revealed the modulation of platelet-associated cytokine levels in COVID-19, pointing to a direct contribution of platelets to the plasmatic cytokine load. Moreover, we demonstrate that platelets release their alpha- and dense-granule contents and phosphatidylserine-exposing extracellular vesicles. Functionally, platelets were hyperactivated in COVID-19 subjects, with aggregation occurring at suboptimal thrombin concentrations. Furthermore, platelets adhered more efficiently onto collagen-coated surfaces under flow conditions.

Conclusions These data suggest that platelets could participate in the dissemination of SARS-CoV-2 and in the overwhelming thrombo-inflammation observed in COVID-19. Thus, blockade of platelet activation pathways may improve outcomes in this disease.

22) Arévalo, A. P., et al. “Ivermectin reduces in vivo coronavirus infection in a mouse experimental model.” Scientific Reports 11.1 (2021): 1-12.
In conclusion, ivermectin diminished the MHV viral load and disease in the mice, being a useful model for further understanding this therapy against coronavirus diseases.

23) Ivermectin, Covid Golden Bullet ? Prof PAUL MARIK in conversation with Solly Kramer & Friends.Feb 9, 2021

24) Hill, Andrew, et al. “Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection.” (2021).
Ivermectin is an antiparasitic drug being investigated for repurposing to SARS-CoV-2. In-vitro, ivermectin showed limited antiviral activity and a COVID-19 animal model demonstrated pathological benefits but no effect on viral RNA. This meta-analysis investigated ivermectin in 18 randomized clinical trials (2282 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv and trial registries. Ivermectin was associated with reduced inflammatory markers (C-Reactive Protein, d-dimer and ferritin) and faster viral clearance by PCR. Viral clearance was treatment dose- and duration-dependent. In six randomized trials of moderate or severe infection, there was a 75% reduction in mortality (Relative Risk=0.25 [95%CI 0.12-0.52]; p=0.0002); 14/650 (2.1%) deaths on ivermectin; 57/597 (9.5%) deaths in controls) with favorable clinical recovery and reduced hospitalization.

25) Pandemic Parallax View Dr Pierre Kory Testimony Senate Homeland Security Committee Hearing on Medical Response to COVID-19 Senator Ben Johnson (R-WI), Chairman
December 8, 2020

Mountains for many centers and countries around the world showing the miraculous effectiveness of ivermectin. It basically obliterates transmission of this virus. If you take it you will not get sick.
We have evidence that ivermectin is effective, not only in prophylaxis, in the prevention. If you take it you will not get sick. We just came across a trial last night from Argentina, by the lead investigator of ivermectin in Argentina, Dr Hector Carvallo. They prophylaxed 800 healthcare workers. Not one got sick. In the 400 that they didn’t prophylax with ivermectin, 58% got sick. 237 of those 400 got sick. If you take it you will not get sick. It has immense and potent antiviral activity.

I’m a lung specialist. I’m an ICU specialist. I’ve cared for more dying Covid patients than anyone can imagine. They’re dying because they can’t breath. They can’t breath. They’re on high-level oxygen delivery devices, they’re on non-invasive ventilators and/or they’re sedated and paralyzed and attached to mechanical ventilators that breath for them. And I watch them every day. They die. By the time they get to me in the ICU they’re already dying. They’re almost impossible to recover.

Earlier treatment is key. We need to off-load the hospitals. We are tired. I can’t keep doing this. If you look at my manuscript and if I have to go back to work next week any further deaths are going to be needless deaths and I cannot be traumatized by that. I cannot keep caring for patients when I know that they could have been saved with earlier treatment and that drug that will treat them and prevent the hospitalization is ivermectin.

The amount of evidence to show that ivermectin is life-saving and protective is so immense and the drug is so safe, my colleagues have talked about it. It must be instituted and implemented.

we now have 11 randomized control trials. Every one of those control trials show that in the ivermectin treated group, lives are saved, there’s less need for hospitalization, there’s less transmission, less case counts. It is a fundamentally and powerfully effective therapy against covid-19.

26) December 8, 2020 Medical Response to COVID-19 The Senate Homeland Security and Governmental Affairs Committee heard from medical professionals who advocate for alternative COVID-19…

27)  YouTube Nuked Two Videos Of A Senate Hearing On COVID-19 Treatments
January 28, 2021 By Jordan Davidson Sen. Ron Johnson said YouTube, which is owned by Google, removed two videos from a Senate hearing about COVID-19 treatments from its platform on Wednesday.

28)  Doctor pleads for review of data on ivermectin as COVID-19 treatment during Senate hearing
By Kelly Hayes December 8, 2020 FOX TV Digital Team

useful information can nevertheless be salvaged from outcomes for this study’s IVM treatment arm, in which no deaths and generally mild symptoms occurred, with AEs typical for high-dose IVM (replicated in the control group) that were generally mild and transient.

29) Scheim, David. “Ivermectin sales in Valle del Cauca, Colombia, patterns of AEs, and other background re López-Medina et al. 2021.” (2021).

30) Paul Marik, MD., Chief of Pulmonary and Critical Care Medicine Eastern Virginia Medical School, Norfolk, VA. Paul Marik, MD is one of the top ICU critical care academic doctors in the nation.(1-2) Dr. Marik wrote a Definitive 37 page Guide with 316 references: EVMS Critical Care COVID-19 Management Protocol 10-29-2020.

Click to access EVMS_Critical_Care_COVID-19_Protocol.pdf

30) Paul Marik, MD., Chief of Pulmonary and Critical Care Medicine Eastern Virginia Medical School, Norfolk, VA. Paul Marik, MD is one of the top ICU critical care academic doctors in the nation.(1-2) Dr. Marik wrote a Definitive 37 page Guide with 316 references: EVMS Critical Care COVID-19 Management Protocol 10-29-2020.

31) Kory, Pierre, et al. “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.” American Journal of Therapeutics 28.3 (2021): e299.
Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin. Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified.

32) The Story Of Ivermectin And COVID-19  Video Documentary

33) This is example of Internet Censorship of any discussion of Ivermectin for Covid by Big Tech on You Tube: 9/6/21 Video Interview Dr Paul Marik discussing Ivermectin for Covid. This video was deleted by You Tube.

==================== ================ ===========

34) Doctor Pierre Cory Testifies on Ivermectin for Covid at Senate Homeland Security Hearing on Covid-19 Treatments Tuesday, December 7, 2020.


===========================================

35) Emergency Room MD  Dr. Rochagné Kilian formerly of Grey Bruce Heath Services,Owen Sound Ontario, discusses massively elevated D-dimer levels indicating extensive micro-thrombosis (microscopic blood clotting) in patients caused by Covid-19 virus and asked the question “could this also occur with the COVID-19 vaccines ?”. On October 27, 2021, the Regulatory Agency of Ontario Cancad suspended her medical license.

36) Lippi, Giuseppe, Fabian Sanchis-Gomar, and Brandon M. Henry. “COVID-19: unravelling the clinical progression of nature’s virtually perfect biological weapon.” Annals of translational medicine 8.11 (2020).

37) Lima-Morales, René, et al. “Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico.” International Journal of Infectious Diseases 105 (2021): 598-605.

There is an urgent need for effective treatments to prevent or attenuate lung and systemic inflammation, endotheliitis, and thrombosis related to COVID-19. This study aimed to assess the effectiveness of a multidrug-therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid (“TNR4” therapy) to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico.
Design and methods A comparative effectiveness study was performed among 768 confirmed SARS-CoV-2 cases aged 18–80 years, who received ambulatory care at the Ministry of Health of Tlaxcala. A total of 481 cases received the TNR4 therapy, while 287 received another treatment (comparison group). All participants received home visits and/or phone calls for clinical evaluation during the 14 days after enrollment.
Results Nearly 85% of cases who received the TNR4 recovered within 14 days compared to 59% in the comparison group. The likelihood of recovery within 14 days was 3.4 times greater among the TNR4 group than in the comparison group. Patients treated with TNR4 had a 75% and 81% lower risk of being hospitalized or death, respectively, than the comparison group.
Conclusions TNR4 therapy improved recovery and prevented the risk of hospitalization and death among ambulatory COVID-19 cases.

39) Karale, Smruti, et al. “A Meta-analysis of Mortality, Need for ICU admission, Use of Mechanical Ventilation and Adverse Effects with Ivermectin Use in COVID-19 Patients.” medRxiv (2021).

40) Ivermectin and CV19 May 7th, 2021 By Will Block

41) Martha, Januar Wibawa, et al. “Active Prescription of Low-dose Aspirin During or Prior to Hospitalization and Mortality in COVID-19—A Systematic Review and Meta-analysis of Adjusted Effect Estimates.” International Journal of Infectious Diseases (2021).

42) Database of all ivermectin COVID-19 studies. 121 studies, 77 peer reviewed, 64 with results comparing treatment and control groups.

43) Santin, A. D., et al. “Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19.” New Microbes and New Infections 43 (2021).

In 2015, the Nobel Committee for Physiology or Medicine, in its only award for treatments of infectious diseases since six decades prior, honoured the discovery of ivermectin (IVM), a multifaceted drug deployed against some of the world’s most devastating tropical diseases. Since March 2020, when IVM was first used against a new global scourge, COVID-19, more than 20 randomized clinical trials (RCTs) have tracked such inpatient and outpatient treatments. Six of seven meta-analyses of IVM treatment RCTs reporting in 2021 found notable reductions in COVID-19 fatalities, with a mean 31% relative risk of mortality vs. controls. During mass IVM treatments in Peru, excess deaths fell by a mean of 74% over 30 days in its ten states with the most extensive treatments. Reductions in deaths correlated with the extent of IVM distributions in all 25 states with p < 0.002. Sharp reductions in morbidity using IVM were also observed in two animal models, of SARS-CoV-2 and a related betacoronavirus. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, possibly yielding full efficacy against emerging viral mutant strains.

44) Bryant, Andrew, et al. “Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis and trial sequential analysis to inform clinical guidelines.” (2021).

45) Kory, Pierre, et al. “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.” American Journal of Therapeutics 28.3 (2021): e299.

46) Lima-Morales, René, et al. “Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico.” Int J of Infect Dis 105 (2021): 598-605. Patients treated with TNR4 had a 75% and 81% lower risk of being hospitalized or death, respectively, than the comparison group.

47) Hill, Andrew, et al. “Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection.” (2021). In six randomized trials of moderate or severe infection, there was a 75% reduction in mortality) with favorable clinical recovery and reduced hospitalization.

Ivermectin reduces the risk of death from COVID-19 -a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance. (Latest version v1.2 – 6 Jan 2021) January 2021 Project: Ivermectin to prevent and treat COVID-19 Authors: Theresa A Lawrie

48) Dixit, Alok, Ramakant Yadav, and Amit Vikram Singh. “Ivermectin: potential role as repurposed drug for COVID-19.” The Malaysian journal of medical sciences: MJMS 27.4 (2020): 154.

49) Chamie-Quintero, Juan, Jennifer A. Hibberd, and David Scheim. “Ivermectin for COVID-19 in Peru: 14-fold reduction in nationwide excess deaths then 13-fold increase after ivermectin use restricted.” (2021).

50) Vora, Agam. “Ivermectin as a potential therapy for COVID-19.” indian j of tuberculosis 67.3 (2020): 448.

51) Lehrer, Steven, and Peter H. Rheinstein. “Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2.” in vivo 34.5 (2020): 3023-3026.

52) Hellwig, Martin D., and Anabela Maia. “A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin.” Int journal of antimicrobial agents 57.1 (2021): 106248.

53) Arévalo, A. P., et al. “Ivermectin reduces in vivo coronavirus infection in a mouse experimental model.” Scientific Reports 11.1 (2021): 1-12.

54) de Melo, Guilherme Dias, et al. “Anti-COVID-19 efficacy of ivermectin in the golden hamster.” BioRxiv (2020).[11]

55) Arévalo AP, et al. Ivermectin reduces in vivo coronavirus infection in a mouse experimental model. Scient Reports 2021;11(1):7132.

56) Kazi L et al Expression of hemagglutinin esterase protein from recombinant mouse hepatitis virus enhances neurovirulence. J Virol 2005;79(24):15064–73

57) (retracted article) Zaidi, Asiya Kamber, and Puya Dehgani-Mobaraki. “The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article.” The Journal of Antibiotics (2021): 1-13.  RETRACTED ARTICLE

58) Lehrer, Steven, and Peter H. Rheinstein. “Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2.” in vivo 34.5 (2020): 3023-3026.

59) Zhang, X., et al. “Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice.” Inflammation Research 57.11 (2008): 524-529.

60) Caly, Leon, et al. “The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.” Antiviral research 178 (2020): 104787.

61) Crump, Andy, and Satoshi Omura. “Ivermectin, Wonder Drug from Japan: the human use perspective.” Proceedings of the Japan Academy, Series B 87.2 (2011): 13-28.

62) How many mechanisms do you need? Ivermectin protects us from Covid in 20 ways by JoNova

63) Ivermectin for COVID-19: real-time meta analysis of 65 studies
Covid Analysis, Nov 12, 2021, Version 145 [BBC, GMK response]

Jeffrey Dach MD
7450 Griffin Road, Suite 190
Davie, Fl 33314
954-792-4663
www.jeffreydachmd.com
www.drdach.com
Heart Book by Jeffrey Dach
www.naturalmedicine101.com
www.bioidenticalhormones101.com
www.truemedmd.com

Click Here for: Dr Dach’s Online Store for Pure Encapsulations Supplements
Click Here for: Dr Dach’s Online Store for Nature’s Sunshine Supplements

Web Site and Discussion Board Links:

jdach1.typepad.com/blog/
disc.yourwebapps.com/Indices/244066.html
disc.yourwebapps.com/Indices/244067.html
http://sci.med.narkive.com/covV2Qo2/jeffrey-dach-book-announcment-natural-medicine-101

Disclaimer

The reader is advised to discuss the comments on these pages with his/her personal physicians and to only act upon the advice of his/her personal physician. Also note that concerning an answer which appears as an electronically posted question, I am NOT creating a physician — patient relationship. Although identities will remain confidential as much as possible, as I can not control the media, I can not take responsibility for any breaches of confidentiality that may occur.

Link to this Article

Copyright (c) 2018 Jeffrey Dach MD All Rights Reserved. This article may be reproduced on the internet without permission, provided there is a link to this page and proper credit is given. See Repost Guidelines.

FAIR USE NOTICE: This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of issues of significance. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.

Serving Areas of: Hollywood, Aventura, Miami, Fort Lauderdale, Pembroke Pines, Miramar, Davie, Coral Springs, Cooper City, Sunshine Ranches, Hallandale, Surfside, Miami Beach, Sunny Isles, Normandy Isles, Coral Gables, Hialeah, Golden Beach ,Kendall,sunrise, coral springs, parkland,pompano, boca raton, palm beach, weston, dania beach, tamarac, oakland park, boynton beach, delray,lake worth,wellington,plantation

 

Last updated on by Jeffrey Dach MD

2 thoughts on “Ivermectin for Covid, The Failure of American Medicine

  1. I received this email from: Patrick Chambers MD, Department of Pathology, Torrance Memorial Medical Center,

    Subject: COVID vaccine, D-dimers, complement, IVM

    Message Body:
    A collective thank you for all you do.
    You’re absolutely correct. CD147 is central to the pathogenesis of COVID-19 and the post vaccination complications. And ivermectin is perfect for both.

    Articles on COVID by Patrick Chambers MD

    Chambers, Patrick William. “COVID-19, ARDS, ACOVCS, MIS-C, KD, PMIS,
    TSS, MIS-A: Connecting the Alphabet?
    .” (2020).

Leave a Reply